Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)

On April 28, 2026, Canaccord lowered its terms people connected Compass Therapeutics, Inc. (NASDAQ:CMPX) to $7 from $13 and maintained a Buy rating. The steadfast said Tovecimig+paclitaxel showed improved progression-free endurance versus paclitaxel monotherapy, but noted that 54% crossover analyzable the mentation of immoderate wide endurance payment successful the ITT population. Canaccord added that portion the progressive limb showed numerically amended wide endurance among patients who did not crossover, it does not expect this to beryllium capable for afloat FDA approval.

In a akin move, Stifel reduced its terms people connected Compass Therapeutics, Inc. (NASDAQ:CMPX) to $6 from $12 portion keeping a Buy rating. Stifel said COMPANION-002 secondary endpoint information enactment the efficacy of tovecimig, shifting the treatment toward however the FDA whitethorn construe the results. The steadfast noted that respective questions are apt to signifier the near-term communicative but reiterated its Buy rating, pointing to tovecimig optionality and an earlier-stage pipeline with upcoming catalysts.

Meanwhile, Jefferies said the 63% selloff successful Compass Therapeutics appears “an over-reaction,” citing the company’s information and the biliary tract crab opportunity, portion adding that the trial’s crossover plan “confounds the ITT readout” adjacent arsenic it maintained a Buy standing and a $9 terms target.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is simply a clinical-stage oncology-focused biopharmaceutical institution processing antibody-based therapeutics for the attraction of assorted quality diseases successful the United States.

While we admit the imaginable of CMPX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.